First Tracks Biotherapeutics Inc
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- First Tracks Biotherapeutics Inc, a clinical-stage biotechnology company focused on developing antibody therapeutics for autoimmune and inflammatory diseases, operates as an independent entity with its strategic activity centered on immunology drug programs and clinical development. Main Products and Services - ANB033: CD122 antagonist targeting autoimmune inflammatory pathways; currently in Phase 1b trials for celiac disease and eosinophilic esophagitis, aiming to modulate pathogenic T cell activity. - ANB101: BDCA2 modulator in early-stage development; designed to regulate plasmacytoid dendritic cell signaling to mitigate inflammatory responses; in Phase 1a exploratory studies. - Rosnilimab (formerly referenced as a lead candidate): selective pathogenic T cell depleter; advanced in clinical development for autoimmune indications such as rheumatoid arthritis, with ongoing Phase 2b evaluation. - End-to-end development services: preclinical to clinical development planning; biomarker strategy and translational research support; manufacturing process development and scale-up activities. - Regulatory and companion services: regulatory strategy planning, IND/enrollment support, and data packages for potential accelerated pathways. Latest Major Company Changes - Nasdaq listing and public debut: launches on Nasdaq with a stated cash position of approximately $180 million, establishing a two-year cash runway to advance clinical programs and operations. - Private financing: completes a private placement raising significant capital (reported as part of an up-front funding package), reinforcing liquidity for ongoing Phase 1/2 trials and future pipeline expansion. - Pipeline expansion and program initiation: announces multiple development programs (ANB033, ANB101, and Rosnilimab) across indications including celiac disease, eosinophilic esophagitis, and rheumatoid arthritis, signaling a diversified autoimmune portfolio with staged clinical milestones. - Corporate affiliation context: positioned as an independent clinical-stage entity focusing on immune modulation therapies, with public market visibility enhancing investor access and potential collaborations. - Strategic partnerships and collaborations: pursuing alliances and collaborations to accelerate clinical development, leverage external expertise, and broaden the pipeline’s reach in immunology indications. - Organizational and operational growth: expanding clinical trial activity and site networks to support multi-program development; ongoing manufacturing and process development plans aligned with advancing lead candidates. Additional Context - Industry and segments: biotechnology; immunology and autoimmunity therapeutic development; clinical-stage drug development; biopharmaceutical manufacturing and regulatory affairs support. - Target markets and customers: biotechnology and pharmaceutical partners, contract research organizations, investors, and potential pharmaceutical licensees seeking novel autoimmune therapies. - Geographic operations: headquartered in the United States with development activities and clinical trials conducted across multiple international sites; regulatory submissions and potential commercialization activities pursued globally. - Founding year and headquarters: publicly described as established in 2025 with headquarters in San Diego, California, United States. - Subsidiaries/parent relationships: positioned as an independent company within the broader biotechnology ecosystem; publicly traded under the ticker TRAX with strategic ties to general market participants and potential parent/affiliate relationships evolving as the company scales.
Company News
First Tracks Biotherapeutics Announces $200 Million Private Placement
First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptor
First Tracks’ ANB033 Clears Key Phase Ib Celiac Disease Study Goals
First Tracks' ANB033 Clears Key Phase Ib Celiac Disease Study Goals
First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday
First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
Insider Selling: First Tracks Biotherapeutics (NASDAQ:TRAX) Director Sells $1,758,286.70 in Stock
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
First Tracks Biotherapeutics (NASDAQ:TRAX) Receives Consensus Rating of “Moderate Buy” from Analysts
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
First Tracks: Huge Cash Reserves Will Not Sustain Testing For Long